Datasets and metadata supporting the published article: Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models

The study investigated the effects of LG268, a Retinoid X Receptor (RXR) agonist, as an immune modulator in the tumor microenvironment of two genetically and histologically distinct mouse models of breast cancer.<br><b>Data access:</b> The datasets supporting all the figures in this published article are publicly available in the figshare repository (as part of this data record, <b>https://doi.org/10.6084/m9.figshare.9944942</b>) and in the supplementary files of the article.<br><br><b>Ethical approval:</b> All animal studies were done in accordance with protocols approved by the Institutional Animal Care and Use Committee at Michigan State University. <br><b>Study aims and methodology: </b>The present study aimed to examine the immunomodulatory effects of LG268, an RXR agonist, in MMTV-Neu and PyMT mouse models of human epidermal growth factor receptor 2 (HER2) positive breast cancer and triple negative breast cancer (TNBC), respectively.The following cell lines were cultured: RAW 264.7 mouse macrophage-like (ATCC) cells, E18-14C-27 cells, THP-1 (ATCC) cells, SK-BR-3 (ATCC) cells and THP-1 cells.Western blotting was performed on whole cell lysates of cells treated with drugs. Western blotting was also performed on homogenised tumors or mammary glands of mice treated with drug or a control diet.Flow cytometry was carried out on cells derived from the tumor, mammary gland and spleen removed from MMTV-neu or MMTV-PyMT female mice. For more details on the methodology, please see the related article. <br><b>Dataset descriptions:</b> The datasets supporting the figures in the published article are described in table <b>Leal et. al.xlsx </b>and are part of this data record. All four datasets are in .xlsx file format.<br><b>Figure 7 dataset.xlsx: </b>Data on the expression levels of PD-L1 in cancer cells and macrophages after treatment with LG268 or bexarotene.<br><b>MMTV-Neu immune and protein data.xlsx:</b> Data on MMTV-Neu mice including tumor and spleen weight, tumor immune cell populations, spleen immune cell populations and mammary gland immune cell populations.<br><b>PCR and flow CD3 activation.xlsx</b>: Quantitative PCR data to determine the levels of FOXP3 and data on CD3 T cells stimulated with anti-CD3 and treated with LG268. Activation of CD4 and CD8 was evaluated by flow cytometry<br><b>PyMT data sets.xlsx:</b> Data on PyMT mice, including tumor and spleen weight, tumor immune cells, mammary gland immune cells and spleen cells. <br>

本研究探讨了视黄醇X受体（Retinoid X Receptor, RXR）激动剂LG268作为免疫调节剂，在两种遗传与组织学特征各异的乳腺癌小鼠模型的肿瘤微环境中的作用效果。<br><b>数据获取：</b>支撑本文所有图表的数据集可于figshare知识库（本数据记录的组成部分，<b>https://doi.org/10.6084/m9.figshare.9944942</b>）以及本文的补充材料中公开获取。<br><br><b>伦理审批：</b>所有动物实验均严格遵循密歇根州立大学机构动物护理与使用委员会批准的实验方案开展。<br><b>研究目的与方法：</b>本研究旨在分别探究RXR激动剂LG268对人表皮生长因子受体2（HER2）阳性乳腺癌MMTV-Neu小鼠模型，以及三阴性乳腺癌（TNBC）PyMT小鼠模型的免疫调节作用。本研究培养了以下细胞系：RAW 264.7小鼠巨噬细胞样（ATCC）细胞、E18-14C-27细胞、THP-1（ATCC）细胞、SK-BR-3（ATCC）细胞及THP-1细胞。对药物处理后的细胞全细胞裂解物进行蛋白质印迹实验；同时对药物处理组或对照饮食处理的小鼠的肿瘤或乳腺组织匀浆开展蛋白质印迹分析。采用流式细胞术对取自MMTV-neu或MMTV-PyMT雌性小鼠的肿瘤、乳腺及脾脏来源的细胞进行检测。如需了解更多实验方法细节，请参阅相关研究论文。<br><b>数据集说明：</b>支撑本文发表图表的数据集详见表格<b>Leal et. al.xlsx</b>且均属于本数据记录的组成部分。所有4个数据集均采用.xlsx文件格式存储。<br><b>Figure 7 dataset.xlsx:</b>包含LG268或贝沙罗汀（bexarotene）处理后，癌细胞与巨噬细胞中程序性死亡配体1（PD-L1）的表达水平数据。<br><b>MMTV-Neu immune and protein data.xlsx:</b>包含MMTV-Neu小鼠的相关数据，包括肿瘤与脾脏重量、肿瘤免疫细胞群、脾脏免疫细胞群及乳腺免疫细胞群数据。<br><b>PCR and flow CD3 activation.xlsx:</b>用于检测叉头框P3（FOXP3）表达水平的定量聚合酶链式反应数据，以及经抗CD3刺激并使用LG268处理的CD3 T细胞相关数据；通过流式细胞术评估CD4与CD8的活化情况。<br><b>PyMT data sets.xlsx:</b>包含PyMT小鼠的相关数据，包括肿瘤与脾脏重量、肿瘤免疫细胞、乳腺免疫细胞及脾脏细胞数据。